OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $198.51 -6.49 (-3.17%) As of 07/3/2025 12:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Genmab A/S Stock (OTCMKTS:GNMSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genmab A/S alerts:Sign Up Key Stats Today's Range$198.51▼$203.0050-Day Range$188.80▼$224.3052-Week Range$170.00▼$292.80Volume24 shsAverage Volume37 shsMarket Capitalization$13.12 billionP/E Ratio11.26Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company operates research and development facilities across Europe and maintains a global presence through strategic partnerships. Over two decades, Genmab has transitioned from a regional biotech start-up into a fully integrated R&D-driven organization with a focus on advancing novel antibody formats and immuno-oncology solutions. At the core of Genmab’s innovation is its proprietary antibody platforms, including the DuoBody® bispecific technology and HexaBody® Fc-enhanced platform, which enable the creation of multi-specific and high-potency antibody candidates. The company’s pipeline encompasses a broad array of clinical- and preclinical-stage molecules targeting hematologic malignancies, solid tumors, and autoimmune conditions. Genmab’s collaborative agreements with leading pharmaceutical companies, such as Janssen and Novartis, have yielded several approved therapies, including ofatumumab-based treatments and daratumumab products, underscoring its ability to translate early-stage research into commercially successful medicines. Genmab serves patients worldwide through its partnerships and sublicensees, with a particular focus on markets in North America, Europe and Asia-Pacific. The company leverages a hybrid model that combines in-house expertise in antibody design, process development and regulatory affairs with the global reach of strategic collaborators. Under the leadership of CEO David L. Junio and an experienced executive team, Genmab continues to expand its pipeline, invest in next-generation antibody technologies and pursue regulatory approvals for novel therapies. This sustained focus on innovation and collaboration positions Genmab as a notable player in the competitive landscape of biopharmaceutical R&D.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreGNMSF MarketRank™: Genmab A/S scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genmab A/S. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 11.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 11.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 111.8, which indicates bearish sentiment.Change versus previous monthShort interest in Genmab A/S has recently decreased by 62.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 111.8, which indicates bearish sentiment.Change versus previous monthShort interest in Genmab A/S has recently decreased by 62.09%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.93 News SentimentGenmab A/S has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Read more about Genmab A/S's insider trading history. Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Stock News HeadlinesGenmab Completes Share Buy-back ProgramJune 30, 2025 | tipranks.comGenmab A/S (GNMSF) Stock Price, Quote, News & Analysis - Seeking AlphaJune 24, 2025 | seekingalpha.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025. | Banyan Hill Publishing (Ad)Genmab A/S Updates Articles of Association for Strategic GrowthJune 18, 2025 | tipranks.comGenmab Discloses Managerial Share Transactions in Compliance with RegulationsJune 17, 2025 | tipranks.comGenmab A/S Updates Articles of Association to Enhance Capital FlexibilityJune 16, 2025 | tipranks.comGenmab Executes Share Buy-back Transactions in June 2025June 16, 2025 | tipranks.comGenmab Advances Share Buy-back Program in June 2025June 10, 2025 | tipranks.comSee More Headlines GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $207.38 at the start of the year. Since then, GNMSF shares have decreased by 4.3% and is now trading at $198.5060. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Thursday, May, 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The firm had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million. Genmab A/S had a trailing twelve-month return on equity of 19.23% and a net margin of 35.11%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2025Today7/03/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:GNMSF CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees2,682Year Founded1999Profitability EPS (Trailing Twelve Months)$17.63 Trailing P/E Ratio11.26 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.14 billion Net Margins35.11% Pretax Margin40.96% Return on Equity19.23% Return on Assets15.44% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.32 Sales & Book Value Annual Sales$3.12 billion Price / Sales4.20 Cash Flow$14.70 per share Price / Cash Flow13.50 Book Value$80.53 per share Price / Book2.46Miscellaneous Outstanding Shares66,070,000Free Float65,057,000Market Cap$13.12 billion OptionableNot Optionable Beta0.91 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:GNMSF) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.